Holen Sie sich die Stockscreener-App
1.14
0.87%
-0.01
Schlusskurs vom Vortag:
$1.15
Offen:
$1.14
24-Stunden-Volumen:
236.74K
Relative Volume:
0.20
Marktkapitalisierung:
$1.23M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-98.30M
KGV:
-0.1581
EPS:
-7.2097
Netto-Cashflow:
$-8.72M
1W Leistung:
+0.88%
1M Leistung:
-50.43%
6M Leistung:
-74.09%
1J Leistung:
+49.21%
1-Tages-Spanne:
$1.11
$1.1784
1-Wochen-Bereich:
$1.0401
$1.2899
52-Wochen-Spanne:
$0.541
$30.30
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Firmenname
Zyversa Therapeutics Inc
Sektor
Branche
Telefon
908-370-5102
Adresse
217 W. MAIN STREET, SOMERVILLE
Vergleichen Sie ZVSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ZVSA | 1.138 | 1.23M | 0 | -98.30M | -8.72M | -7.2097 |
| VRTX | 450.21 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.87 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 599.22 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.97 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.47 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ZyVersa reports progress on stroke-related heart injury treatment By Investing.com - Investing.com South Africa
ZyVersa reports progress on stroke-related heart injury treatment - Investing.com
ZyVersa Therapeutics Announces Peer-Reviewed Publication - GlobeNewswire
ZyVersa's IC 100 Shows Promise in Stroke Prevention, Phase 1 Trials Set for 2025 | ZVSA Stock News - StockTitan
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeu - GuruFocus.com
ZyVersa Therapeutics Reports Q3 Progress and Outlook - TipRanks
ZyVersa Therapeutics Inc (ZVSA) Quarterly 10-Q Report - Quartzy
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update - GlobeNewswire
ZyVersa Plans Key Clinical Trials as Q3 Losses Narrow, Faces Cash Needs | ZVSA Stock News - StockTitan
ZVSA stock plunges to 52-week low, hitting $1.34 amid market challenges - Investing.com UK
United States shares higher at close of trade; Dow Jones Industrial Average up 3.56% - Investing.com India
ZyVersa Therapeutics, Inc. (ZVSA): A 38.8% Stock Surge Highlights Innovative Approach to Inflammatory Disease with IC 100 - BP Journal
Agrify Corporation (AGFY): Strategic Restructuring and New Leadership Boosts Stock by 33% as Green Thumb Invests $20 Million - BP Journal
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Stock Market Movers Today • Top Gainers & Losers - Benzinga
"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge" - openPR
Wall Street-Heavily Traded - WDRB
Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings - Benzinga
S&P 500 Gains 1%; Vimeo Shares Spike Higher - Benzinga
Bionomics Limited (BNOX): Stock Soars Over 162% Following Milestone Payment from Carina Biotech - BP Journal
U.S. Stock market: Zoomcar Holdings (+192.21%), Avalon GloboCare (+56.73%), and Vimeo (+40.85%) experience significant gains during mid day trading - Business Upturn
ZyVersa (ZVSA) Stock Gains Momentum With Latest Research - Stocks Telegraph
U.S. Stock market: Zoomcar Holdings up 87.10%, Avalon GloboCare jumps 57.14%, Vimeo rises 44.07% among top gainers - Business Upturn
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
ZyVersa reports progress on obesity inflammation treatment By Investing.com - Investing.com South Africa
ZyVersa reports progress on obesity inflammation treatment - Investing.com India
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - The Manila Times
ZyVersa Therapeutics Highlights Published Data - GlobeNewswire
ZyVersa's Breakthrough: New Data Shows Promise for Type 2 Diabetes Prevention | ZVSA Stock | ZVSA Stock News - StockTitan
Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs - The Manila Times
ZyVersa Therapeutics Highlights Review Article Supporting - GlobeNewswire
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
ZyVersa reports obesity-linked brain inflammation study By Investing.com - Investing.com Canada
ZyVersa reports obesity-linked brain inflammation study - Investing.com
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases - GlobeNewswire
ZVSA stock touches 52-week low at $2.07 amid sharp annual decline - Investing.com Canada
ZVSAZyVersa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
ZyVersa advances obesity drug with key milestones ahead - Investing.com India
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months - The Manila Times
ZyVersa advances obesity drug with key milestones ahead By Investing.com - Investing.com UK
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured - GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to - The Bakersfield Californian
ZyVersa forms new SAB for obesity treatment advancement By Investing.com - Investing.com South Africa
ZyVersa forms new SAB for obesity treatment advancement - Investing.com India
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications - The Manila Times
ZyVersa Therapeutics Forms New Scientific Advisory Board to - GlobeNewswire
Proteinuria Therapeutics Strategic Business Report 2024: Innovations in Biomarker-Based Diagnosis Sustain Growth in Proteinuria Therapeutics MarketForecasts to 2030 - 24matins.uk
Finanzdaten der Zyversa Therapeutics Inc-Aktie (ZVSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):